Gunnar Lohm
Overview
Explore the profile of Gunnar Lohm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lohm G, Knornschild F, Neumann K, Budach V, Schwartz S, Burock S, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339285
In patients with prostate cancer (PCa), salvage radiotherapy (SRT) for biochemical progression (BP) after radical prostatectomy (RP) improves PCa-specific survival. However, no prospective randomized trials have compared the effect of...
2.
Lohm G, Neumann K, Budach V, Wiegel T, Hoecht S, Gollrad J
Strahlenther Onkol
. 2017 Dec;
194(4):325-332.
PMID: 29255924
Background: In patients with prostate cancer (PCa) and biochemical progression (BP) after radical prostatectomy (RP), salvage radiotherapy (sRT) improves prostate cancer-specific survival (PCSS), but this evidence is based only on...
3.
Lohm G, Lutcke J, Jamil B, Hocht S, Neumann K, Hinkelbein W, et al.
Strahlenther Onkol
. 2014 Mar;
190(8):727-31.
PMID: 24577132
Background And Purpose: In patients with prostate cancer (PC) and biochemical relapse after radical prostatectomy, salvage radiotherapy (SRT) could improve PC-specific survival (PCSS) but the timing for initiation is still...
4.
Burmeister T, Molkentin M, Meyer C, Lachmann N, Schwartz S, Friedrichs B, et al.
Exp Hematol Oncol
. 2012 Dec;
1(1):6.
PMID: 23211007
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion....
5.
Lohm G, Bottke D, Jamil B, Miller K, Neumann K, Bartkowiak D, et al.
World J Urol
. 2012 Mar;
31(2):423-8.
PMID: 22460203
Purpose: Salvage radiotherapy (SRT) is applied routinely in patients with a biochemical relapse after radical prostatectomy (RP). Although the detection threshold for relapse after RP has steadily been lowered, only...
6.
Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, et al.
Radiother Oncol
. 2011 Nov;
103(2):239-43.
PMID: 22119375
Purpose: Salvage radiotherapy (SRT) is applied routinely in patients with biochemical relapse after radical prostatectomy (RP). However, only ∼30% of these patients achieve a durable response after 10 years. As...
7.
Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, et al.
Strahlenther Onkol
. 2011 Jul;
187(8):467-72.
PMID: 21786112
Purpose: The optimal dose for salvage radiotherapy (SRT) after radical prostatectomy (RP) is still not defined. It should be at least 66 Gy. In the present study, the suitability of...
8.
Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, et al.
Int J Radiat Oncol Biol Phys
. 2008 Oct;
73(4):1009-16.
PMID: 18963539
Purpose: Salvage radiotherapy (SRT) is commonly used to treat patients with biochemical failure after radical prostatectomy (RP). Retrospective series have demonstrated biochemical response in approximately 60-75% of patients, but only...
9.
Hocht S, Lohm G, Moser L, Hinkelbein W
Front Radiat Ther Oncol
. 2008 Jun;
41:77-85.
PMID: 18544988
A biochemical recurrence following prostatectomy is often diagnosed in relatively young and healthy men, and hence deemed very relevant concerning life, given the generally high life expectancy of these patients....